| Autor: |
A. V. Misyurin, T. V. Akhlynina, A. Yu. Baryshnikov, E. V. Aksenova, V. A. Misyurin, Yu. P. Finashutina, A. A. Krutov, N. A. Lyzhko |
| Rok vydání: |
2015 |
| Předmět: |
|
| Zdroj: |
Russian Journal of Biotherapy. 14:29-36 |
| ISSN: |
1726-9784 |
| Popis: |
Tumor antigens recognized by CTLs have been identified several years ago and are major targets for creating anticancer vaccines. PRAME is an antigen which is highly expressed in various malignant tumors including melanomas and hematopoietic malignancies such as acute and chronic leukemias (AML, CML). Technology for producing recombinant antigen PRAME is based on creating a bacterial producer strain containing cDNA of human PRAME gene. We have obtained two producers of recombinant PRAME protein and its N-half, the synthesis of the target protein in the producers occurs in the inclusion bodies. The schemes of isolation and purification of soluble proteins have been developed. The protein purity was approximately 95-96%. The monoclonal antibodies raised against truncated recombinant PRAME were used for PRAME protein analysis by Western blot on the various tumor cells. Specific monoclonal antibodies recognized the native PRAME protein in tumor cell lines as well as in tumor samples from patients. Our findings support the suggestion that this recombinant antigen may be further used as a target for diagnostic and therapeutic approaches. The monoclonal antibodies can be used for immunoassays of tumor samples from patients with hematologic malignancies to reveal clinical features and to monitor tumor progression. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
